Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Hepatocellular 3Neoplasms 2Skin Neoplasms 1Pancreatic Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hepatitis C, Chronic 1Hepatitis B, Chronic 1Colonic Neoplasms 1

Interventions

Photochemotherapy 2pembrolizumab 1peginterferon alfa-2a 1Tomography, Optical Coherence 1Therapeutics 1Surveys and Questionnaires 1Health 1Gefitinib 1Floderm topical cream 1Early Intervention, Educational 1Dimethyl Sulfoxide 1Data Collection 1Chemexfoliation 1Cetuximab 1Biopsy 1Ascorbic Acid 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Skin Neoplasms × peginterferon alfa-2a × Clear all
NCT00423397 2013-12-19

Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer

National Cancer Institute (NCI)

Phase 1/2 Unknown
16 enrolled
Dermatologic

Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡